Ratings Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Delayed Australian S.E. Other stock markets 20:22:19 2024-05-13 EDT			5-day change	1st Jan Change
0.027 ^AUD	-3.57%		-15.62%	+22.73%

05-07	Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer	MT
05-03	Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ACTINOGEN MEDICAL LIMITED	+22.73%	46.09M	-
MODERNA, INC.	+26.37%	44.96B	B-
IQVIA HOLDINGS INC.	-1.01%	42.65B	B
LONZA GROUP AG	+46.00%	41.85B	A
CELLTRION, INC.	-5.31%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B	B
BIO-TECHNE CORPORATION	+6.23%	12.75B	B+
MEDPACE HOLDINGS, INC.	+26.99%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes